Related Experiment Video
Updated: Sep 16, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
The IFN I response in tumor cells is shaped by PARP7-p300/CBP interactions through distinct loss- and
Abstract:
PARP7, a mono-ADP-ribosyl (MAR) transferase, is a key suppressor of the type I interferon (IFN-I) IFNβ in various tumor cells and a validated drug target. This negative regulation is reversed by small-molecule inhibitors of PARP7 catalytic activity, resulting in increased IFN-β expression. Yet, the mechanism of action of PARP7 inhibitors remains unclear because the relevant substrates of PARP7-mediated MARylation are unknown. Using an optimized analog- sensitive chemical genetic (ASCG) approach, we identified the co-activators, p300 and CBP, as nuclear PARP7 substrates. We identified an α-helical domain in PARP7 essential for p300/CBP interaction, MARylation, and proteasome degradation. Disrupting PARP7-p300/CBP interaction prevents PARP7's suppression of IFNβ in colorectal cancer cells. p300/CBP reciprocally regulate PARP7's activity and nuclear localization. Intriguingly, treatment with PARP7 inhibitors increased IFNβ expression more than PARP7 knockout in a p300/CBP-dependent manner. Our findings suggest that in some contexts, IFNβ induction by PARP7 inhibitors occurs via two mechanisms: inhibiting MARylation of p300/CBP (loss-of-function) and stabilizing the PARP7- p300/CBP complex (gain-of-function).
Teaser:
Chemical genetics discovery of p300 and CBP as substrates of PARP7 that are essential for PARP7-mediated regulation of IFNβ via a dual mechanism.
Insights
Poly (ADP-ribose) polymerase 7 (PARP7) regulates type I interferon (IFN-β) by modifying co-activators p300 and CBP. PARP7 inhibitors induce IFN-β via a dual mechanism involving both loss-of-function and gain-of-function effects.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Poly (ADP-ribose) polymerase 7 (PARP7) is a mono-ADP-ribosyl (MAR) transferase that suppresses type I interferon (IFN-β) in tumor cells.
- PARP7 is a validated drug target, and its inhibitors increase IFN-β expression, but the precise mechanism remains unclear due to unknown substrates.
Purpose of the Study:
- To identify nuclear substrates of PARP7 and elucidate the mechanism by which PARP7 inhibitors regulate IFN-β expression.
Main Methods:
- Utilized an optimized analog-sensitive chemical genetic (ASCG) approach to identify PARP7 substrates.
- Investigated the interaction between PARP7, p300, and CBP using biochemical and cellular assays.
- Assessed the impact of disrupting PARP7-p300/CBP interaction on IFN-β expression in colorectal cancer cells.
Main Results:
- Identified co-activators p300 and CBP as nuclear PARP7 substrates.
- Discovered an α-helical domain in PARP7 crucial for p300/CBP interaction, MARylation, and proteasome degradation.
- Demonstrated that disrupting PARP7-p300/CBP interaction inhibits PARP7's suppression of IFN-β.
- Observed that PARP7 inhibitors induce IFN-β more effectively than PARP7 knockout in a p300/CBP-dependent manner.
Conclusions:
- PARP7 regulates IFN-β by MARylating p300/CBP, and this interaction is essential for suppressing IFN-β in cancer cells.
- PARP7 inhibitors induce IFN-β through a dual mechanism: inhibiting p300/CBP MARylation (loss-of-function) and stabilizing the PARP7-p300/CBP complex (gain-of-function).
- These findings provide novel insights into the mechanism of PARP7 inhibitors and their potential in cancer immunotherapy.
Related Concept Videos
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
The Intrinsic Apoptotic Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

